skip
net ir
Japanese
What's New

4507 SHIONOGI & CO., LTD.
President and CEO Isao Teshirogi, Ph.D.
R&D presentation
4523 Eisai Co., Ltd.
Representative Corporate Officer and CEO Haruo Naito
Information Meeting
4536 Santen Pharmaceutical Co., Ltd.
President & CEO Akira Kurokawa
Japan and Asia Business Update
4204 SEKISUI CHEMICAL CO., LTD.
Yoshiyuki Hirai Director, Managing Executive Officer
Presentation of Financial Results for the 3rd Quarter of FY2017
4578 Otsuka Holdings Co., Ltd.
President and Representative Director, CEO Tatsuo Higuchi
FY2017 Financial Results Presentation
3659 NEXON Co., Ltd.
President and Chief Executive Officer Owen Mahoney
Investor Presentation Q4 2017
4507 SHIONOGI & CO., LTD.
Director of the Board, Senior Executive Officer, Senior Vice President, Corporate Strategy Takuko Sawada
3rd Quarter of Fiscal 2017 Financial Results Conference Call
7013 IHI Corporation
Board Director and Executive Officer, General Manager of Finance & Accounting Division Takeshi Yamada
Financial Results for Third Quarter FY2017 (for the year ending March 31, 2018)
4502 Takeda Pharmaceutical Company Limited
President and Chief Executive Officer
Christophe Weber
Consolidated Financial Results for FY2017 Q3
4523 Eisai Co., Ltd.
Ryohei Yanagi Senior Vice President
Q3 FY2017 (Fiscal Year Ending March 31, 2018) Financial Results Presentation
8604 Nomura Holdings, Inc.
CFO Takumi Kitamura
Third Quarter Operating Results for Fiscal Year Ending March 2018
7013 IHI Corporation
Board Director and Executive Officer, General Manager of Finance & Accounting Division Takeshi Yamada
Revisions to the Full-Year Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2018
4503 Astellas Pharma Inc.
Chief Financial Officer Chikashi Takeda
Q3/FY2017 FINANCIAL RESULTS ENDED DECEMBER 31, 2017
4503 Astellas Pharma Inc.
President and CEO Yoshihiko Hatanaka
Q2/FY2017 FINANCIAL RESULTS ENDED SEPTEMBER 30, 2017
8604 Nomura Holdings, Inc.
Group CEO Koji Nagai
Nomura Investment Forum 2017
8630 Sompo Holdings, Inc.
President(Group CEO) Kengo Sakurada
Progress of Mid-term Management Plan
8766 Tokio Marine Holdings, Inc.
President and Group CEO Tsuyoshi Nagano
Mid-Term Business Plan "To Be a Good Company 2017'' 2017 Business Plan Update
4578 Otsuka Holdings Co., Ltd.
Senior Managing Director Atsumasa Makise
FY2017 Q3 Consolidated Financial Results
4507 SHIONOGI & CO., LTD.
President and CEO Isao Teshirogi, Ph.D.
1st Half of Fiscal 2017 Financial Results
4204 SEKISUI CHEMICAL CO., LTD.
Teiji Koge President
Presentation of Financial Results and Progress under Management Plan for the Second Quarter of FY2017
4536 Santen Pharmaceutical Co., Ltd.
Akira Kurokawa President & CEO
Investor Meeting on Q2 FY2017 Results
7013 IHI Corporation
President and Chief Executive Officer
Tsugio Mitsuoka
Financial Results for Second Quarter FY2017(for the year ending March 31, 2018)
4502 Takeda Pharmaceutical Company Limited
President and Chief Executive Officer
Christophe Weber
Earnings Conference for the 2nd Quarter of Fiscal Year 2017
3659 NEXON Co., Ltd.
President and Chief Executive Officer Owen Mahoney
Investor Presentation Q2 2017
8630 Sompo Holdings, Inc.
President(Group CEO) Kengo Sakurada
Progress of Mid-term Management Plan
8766 Tokio Marine Holdings, Inc.
President Tsuyoshi Nagano
Mid.Term Business Plan"To Be a Good Company 2017"FY2017 Business Plan
8604 Nomura Holdings, Inc.
Group COO Tetsu Ozaki
Investor Day
4536 Santen Pharmaceutical Co., Ltd.
Akira Kurokawa President & CEO
Investor Meeting on FY2016 Results and FY2017 Forecasts
4204 SEKISUI CHEMICAL CO., LTD.
President Teiji Koge,
Presentation of Medium-term Management Plan SHIFT 2019-Fusion- (FY2017-FY2019)
4507 SHIONOGI & CO., LTD.
President and CEO Isao Teshirogi, Ph.D.
R&D presentation

Precautions in use
Nomura IR assumes no responsibility for correctness, validity or any other nature of the contents on this server.
No act such as alteration, modification or addition to the contents is permitted.
Since the contents on this server are not intended to solicit investment, our company has no liability for any trouble related to investment made by any audience based on the contents of this site. Investors are required to decide at their own discretion.
Nomura IR assumes no responsibility for correctness, validity or any other nature of information, including its format and details, obtained from any site linked from our site.

up
Download Plug-in
Get Adobe Reader
Windows Media Player
Real Player
Copyright (c) 2004 Nomura Investor Relations Co., Ltd. All Rights Reserved.
NIR